Eli Lilly and Company (NYSE:LLY) introduces an easy-to-use injector pen for its weight-loss and diabetes drug, Mounjaro, in India. Priced at 14,000 Indian rupees ($160.6), the pen aims to tap into the growing diabetes and obesity market in the country. The launch follows Novo Nordisk’s release of a similar weight loss drug, Wegovy, in India.

Eli Lilly previously launched Mounjaro in India through vials in March, making the drug more accessible with the new injector pen. The move is expected to attract more users seeking convenient and efficient administration of the medication.

India’s rising cases of obesity and type 2 diabetes have created a high demand for weight-loss and diabetes treatments, providing a lucrative market for pharmaceutical companies like Eli Lilly. Despite competition from cheaper generic versions of similar drugs in India, Eli Lilly aims to capture a share of this growing market with Mounjaro.

Wall Street shows optimism towards Eli Lilly stock, with an average “Buy” rating and an average implied upside of 28.17%. However, investors seeking higher potential returns with less risk may consider exploring other investment opportunities, such as undervalued AI stocks.

For more investment insights and recommendations, explore reports on the best short-term AI stocks, high-growth consumer stocks, and top growth stocks according to analysts. Disclosure: None.

Read more at Yahoo Finance: Eli Lilly (LLY) Launches Easy Mounjaro Pen in India Amid Growing Diabetes Market